Filing Flows

Filing Flows › Nuvation Bio (NUVB) › Next earnings date

Nuvation Bio (NUVB) earnings: beat the estimate

Nuvation Bio (NUVB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.09 against −$0.10 (+12.4%). Revenue was $45.0M for Q3 2026, +243% year over year. The stock moved -10.7% on the report. It beat the EPS estimate in 40% of the quarters on record.

Last result+12.4% vs estimate
Beat rate40%

The last report

Nuvation Bio reported revenue of $45.0M for the third quarter 2026 (+243% Y/Y), net loss $41.9M: Product Revenue $27.5M, License $17.5M. How it makes money → · Every quarter →

Nuvation Bio: EPS against the estimate, last 5 reportsNuvation Bio: EPS against the estimate, last 5 reportsEstimateReported−$0.15−$0.14Nov 25−$0.04−$0.09Mar 26$0.05$0.04May 26−$0.12−$0.15Aug 26−$0.10−$0.09Nov 26
Latest (Nov 26): Estimate −$0.10, Reported −$0.09.
NUVB: the stock's move on each reportNUVB: the stock's move on each reportNov 4, 2026-10.7%Aug 6, 2026+3.6%May 4, 2026+7.6%Mar 2, 2026-26.2%Nov 3, 2025-7.5%

Nuvation Bio's latest quarter

Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Nuvation Bio beat earnings?

Nuvation Bio (NUVB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.09 against −$0.10 (+12.4%).

When does NUVB report earnings?

The next date is not set yet.

Does Nuvation Bio usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.